Drug Profile
Research programme: cancer therapeutics - Invenra/QIMR Berghofer Medical Research Institute
Latest Information Update: 28 Mar 2021
Price :
$50
*
At a glance
- Originator Invenra; QIMR Berghofer Medical Research Institute
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Mar 2021 No recent reports of development identified for research development in Cancer in USA
- 28 Feb 2017 Invenra and QIMR Berghofer Medical Research Institute enter research collaboration to develop monoclonal antibodies for cancer
- 28 Feb 2017 Early research in Cancer in USA (unspecified route)